Medherant a University of Warwick spin out company developing next generation transdermal drug delivery patch technology, announced the appointment of two new senior executives, Sally Waterman and Angus Hone.
These appointments mark a significant expansion of the Company’s management team to support the business as it moves into clinical development and commercialisation of its ibuprofen TEPI Patch.
Sally Waterman joins the team as COO. She brings over 30 years’ experience in executive management in large pharma, small biotech/biopharma and contract service companies.
Sally has held a wide variety of strategic and operational roles, including leading R&D, and involvement in two IPOs, numerous financing rounds and M&A. Prior to joining Medherant she was Senior VP Corporate Development at Abzena. She is currently the Chairman of OBN.
Angus Hone joins Medherant as CFO. He has over 20 years’ experience in financial management in the pharmaceutical and life sciences sector with extensive CFO/COO experience in VC/PE-backed healthcare, medical diagnostics, life science and software technology companies. He comes to Medherant from Cascade BI, where he acted as Mentor to the CEO. Prior to this he spent 3 years at Enigma Diagnostics, initially as acting CFO and then as CEO.
Nigel Davis, CEO of Medherant, said: “I am delighted to welcome Sally and Angus to the team as we start manufacturing our ibuprofen TEPI Patches and move into clinical trials. Both are highly regarded industry professionals and will add expertise and capability to our management team.”
Nicola Broughton, Head of Universities at Mercia Technologies, said: “It is fantastic to see the senior team at Medherant expanding with new talent. This is a key time for the company as it moves into clinical trials and with the added expertise and valuable experience of Sally and Angus, the business is in an ideal position for its next phase of growth.”